Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?
Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.
Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.
Celgene Corporation, Amgen Inc., and Gilead Sciences Inc. may be good biotech stocks to buy on a sell-off.
The field where the Internet of Things is likely to have the biggest impact is often the field no one associates with it: biotech.
These three companies have the potential to double their share price from current levels. Here's why.
In the multibillion-dollar market for hepatitis C, this company stands above the crowd.
Healthcare stocks with plenty of potential -- and low share prices
AbbVie is reportedly still interested in acquiring additional assets to help it over the Humira patent cliff hump. Would Acadia Pharmaceuticals be a good match for this big pharma?
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?